IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

TW's Take: Gamma-Delta T-Cells is a very hot space and IN8bio is proving to be a leader here. The stock is dramatically undervalued relative...

IN8bio to Present at Biotech Showcase 2023 in San Francisco

TW's Take: expecting good news from their GBM program this coming week before they start presenting to investors in San Francisco. NEW YORK, Jan. 03,...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.